STOCK TITAN
  1. Home
  2. Sec-filings
  3. HLYK
  4. [8-K] HealthLynked Corp Reports Material Event

HealthLynked (HLYK) taps George O’Leary as interim CFO, reshapes C-suite

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

HealthLynked Corp. appointed director George O’Leary, 63, as part-time Interim Chief Financial Officer effective July 13, 2026, under a consulting engagement for three days per week at $15,000 per month. He also received 35,000 stock options with a $3.50 exercise price that vest only if the company receives approval for listing on the Nasdaq Capital Market while he is serving as interim CFO or during a 30-day notice period after termination.

On the same date, Jeremy Daniel ceased serving as Chief Financial Officer and moved into a corporate accounting role, with the company stating the transition did not result from any disagreement with management, the board, or its committees. Effective July 24, 2026, HealthLynked will eliminate the Chief Operating Officer position; incumbent COO Duncan McGillivray will leave that role and continue on an as-needed basis under an Independent Consulting Agreement as Senior Strategic Advisor.

Positive

  • None.

Negative

  • None.

Filing Explained

The July 16 8-K makes a $15,000-per-month interim-CFO consulting commitment effective; the latest quarterly report showed HealthLynked had $23,973 of cash at March 31, 2026, equal to 9.7 days of the last reported operating cash use.

Sources and calculations
  • Cash and equivalents vs quarterly operating cash outflow, in days of cash use $23,973 / ($221,976 / 90) = [object Object]
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Interim CFO monthly fee $15,000 per month Compensation under Interim Chief Financial Officer Consulting Engagement Letter
Interim CFO work schedule 3 days per week Level of service under consulting engagement
Stock options granted 35,000 options Options granted to Interim CFO George O’Leary, vesting upon Nasdaq Capital Market listing approval
Option exercise price $3.50 per share Exercise price of options granted to Interim CFO
Effective date of interim CFO appointment July 13, 2026 Date George O’Leary became Interim Chief Financial Officer
Effective date COO role elimination July 24, 2026 Date Chief Operating Officer position will be eliminated
Interim Chief Financial Officer financial
"appointed George O’Leary, age 63, as its part-time Interim Chief Financial Officer"
An interim chief financial officer is a temporary leader responsible for managing a company's financial activities, such as budgeting, financial planning, and reporting, during a transitional period. Think of it as filling in for a key manager until a permanent replacement is found. For investors, this role is important because it ensures financial stability and clear guidance during times of change or uncertainty.
Nasdaq Capital Market market
"shall vest upon the Company’s successful approval for listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Independent Consulting Agreement financial
"the Company entered into an Independent Consulting Agreement with Mr. McGillivray"
Item 404(a) of Regulation S-K regulatory
"no transactions are required to be reported under Item 404(a) of Regulation S-K"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What executive leadership changes did HealthLynked (HLYK) make in July 2026?
HealthLynked appointed George O’Leary as part-time Interim CFO on July 13, 2026 and eliminated the COO role effective July 24, 2026. Former CFO Jeremy Daniel moved to a corporate accounting role, and former COO Duncan McGillivray became a Senior Strategic Advisor under a consulting agreement.

What are the compensation terms for HealthLynked (HLYK) interim CFO George O’Leary?
George O’Leary will work three days per week as Interim CFO and receive $15,000 per month under a consulting engagement. In addition, he was granted 35,000 stock options with a $3.50 per share exercise price, subject to specific vesting conditions.

What triggers vesting of the 35,000 stock options granted by HealthLynked (HLYK) to its interim CFO?
The 35,000 stock options granted to George O’Leary vest upon HealthLynked’s successful approval for listing on the Nasdaq Capital Market while he is actively serving as Interim CFO or during a 30-day notice period after termination of his agreement.

How did HealthLynked (HLYK) describe the circumstances of CFO Jeremy Daniel’s transition?
HealthLynked stated that Jeremy Daniel ceased serving as CFO on July 13, 2026 and moved into a corporate accounting role. The company specifically noted his transition was not the result of any disagreement with the company, its management, the board, or any board committee.

What is changing with the Chief Operating Officer role at HealthLynked (HLYK)?
Effective July 24, 2026, HealthLynked will eliminate the Chief Operating Officer position as part of efforts to align leadership with operational priorities. COO Duncan McGillivray will cease serving as COO and continue as a Senior Strategic Advisor under an Independent Consulting Agreement.
false 0001680139 0001680139 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 13, 2026

 

HealthLynked Corp.

(Exact name of registrant as specified in charter)

 

Nevada   000-55768   47-1634127
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

1265 Creekside Parkway, Suite 302, Naples FL 34108

(Address of principal executive offices)

 

(800) 928-7144

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Chief Financial Officer 

 

Effective July 13, 2026, HealthLynked Corp., a Nevada corporation (the “Company”), appointed George O’Leary, age 63, as its part-time Interim Chief Financial Officer. Mr. O’Leary has served as a director of the Company since August 6, 2014 and previously served as the Company’s Chief Financial Officer from August 6, 2014 until April 4, 2024.

 

Mr. O’Leary is a financially trained senior executive specializing in innovative strategic problem solving across functional and industry boundaries. Most recently, Mr. O’Leary was CEO of Sono Group NV (Nasdaq: SSM) from April 2024 through December 2025, where he took the company from the OTCQB and uplisted to the Nasdaq Capital Market in September 2025 and as fractional CFO for New America Acquisition I Corp. (NYSE: NWAX-UN) participated in the SPAC IPO on the NYSE in December 2025. Mr. O’Leary is Vice Chairman of Referrizer, LLC, a private marketing automation company, currently offering AI agents to its clients, since January 2016. Mr. O’Leary was the Vice-Chairman of the board of directors of Timios Holdings Corp. from March 2014 through January 2021. From June 2009 to May 2013 Mr. O’Leary was Chairman of the Board and Chief Financial Officer of Protection Plus Securities Corporation until it was sold to Universal Protection Services. From February 2007 to June 2015, Mr. O’Leary was a member of the Board of Directors of NeoMedia Technologies. Mr. O’Leary is founder and President of SKS Consulting of South Florida Corp. (“SKS”) since June 2006 where he works with public and private companies in board representation and/or under consulting agreements providing executive level management expertise, as well as helping the implementation and execution of their companies’ strategic & operational plans.

 

From 1996 to 2000, Mr. O’Leary was Chief Executive Officer and President of Communication Resources Incorporated (“CRI”), where annual revenues grew from $5 million to $40 million during his tenure. Prior to CRI, Mr. O’Leary was Vice President of Operations of Cablevision Industries, where he ran $125 million of business until it was sold to Time Warner. Mr. O’Leary started his professional career as a senior accountant with Peat Marwick and Mitchell (KPMG). Mr. O’Leary holds a B.B.A. degree in Accounting with honors from Siena College.

 

Pursuant to the terms of the Interim Chief Financial Officer Consulting Engagement Letter (the “Engagement Letter”) between the Company and Mr. O’Leary, the parties have agreed that Mr. O’Leary will work three days per week for compensation of $15,000 per month. The Company also issued to Mr. O’Leary 35,000 stock options with an exercise price of $3.50 per share that shall vest upon the Company’s successful approval for listing on the Nasdaq Capital Market while Mr. O’Leary is actively serving as Interim Chief Financial Officer or during any applicable thirty (30) day notice period following termination of this Agreement. The Engagement Letter is attached hereto as Exhibit 10.1.

 

There are no arrangements or understandings between Mr. O’Leary and any other person pursuant to which he was selected for his position. In addition, there are no family relationships between Mr. O’Leary and any directors or executive officers of the Company, and no transactions are required to be reported under Item 404(a) of Regulation S-K between Mr. O’Leary and the Company.

 

1

 

 

Departure of Chief Financial Officer 

 

Effective July 13, 2026, Jeremy Daniel ceased serving as Chief Financial Officer and transitioned to a corporate accounting role with the Company. Mr. Daniel’s transition was not the result of any disagreement with the Company, its management, the Company’s Board of Directors (the “Board”), or any committee of the Board.

 

Departure of Chief Operating Officer

 

Effective July 24, 2026, the Company will eliminate the position of Chief Operating Officer as part of its ongoing efforts to optimize its executive management structure and align its leadership responsibilities with the Company’s current operational priorities, financial resources, and strategic objectives. Accordingly, Duncan McGillivray will cease serving as the Company’s Chief Operating Officer effective July 24, 2026. In connection with this transition, the Company entered into an Independent Consulting Agreement with Mr. McGillivray pursuant to which he will serve as Senior Strategic Advisor on an as-needed basis.

 

Item 9.01.  Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit No.   Exhibit Title or Description
10.1   Interim Chief Financial Officer Consulting Engagement Letter
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HEALTHLYNKED CORP.
   
Date: July 16, 2026 /s/ Michael Dent
  Michael Dent
  Chief Executive Officer and Chairman

 

3

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents